Fresenius Medical Care AG & Co. KGaA

Most Recent

  • uploads///Chart
    Earnings Report

    Shire: Why Analysts Expect Revenue Growth in Q3 2018

    Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.

    By Mike Benson
  • uploads///medic _
    Company & Industry Overviews

    DaVita’s Valuation on September 17

    DaVita currently trades at a forward PE multiple of 15.2x compared to the industry average of 15.1x as of September 17.

    By Mike Benson
  • uploads///healthcre
    Healthcare

    How the Healthcare Sector’s Dividend Yield Stacks Up

    The healthcare industry has an average dividend yield of 1.9%.

    By Amanda Lawrence
  • uploads///akorn transaction highlights
    Company & Industry Overviews

    Akorn Files Lawsuit against Fresenius for Pulling Out of Deal

    For the deal to be terminated, Fresenius will have to prove that Akorn misled regulators and is guilty of severe data breaches.

    By Sarah Collins
  • uploads///financial crisis _
    Company & Industry Overviews

    Why Akorn Tumbled over 33% on April 23

    On April 22, Fresenius (FMS) announced the termination of its $4.3 billion acquisition of Akorn (AKRN).

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018

    Haemonetics (HAE) is currently the number one or number two player in the cell salvage segment in most of the geographies in which the company competes.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Hospital Business Remains 1of HAE’s Key Growth Drivers

    In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%.

    By Margaret Patrick
  • uploads///rd milestones
    Company & Industry Overviews

    Inside Baxter’s Recent Developments in Peritoneal Dialysis Care

    Baxter International’s (BAX) PD (peritoneal dialysis) solutions are among the key growth drivers of the company’s renal therapies business.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Fresenius Medical Care Is a Global Leader in the Dialysis Segment

    In addition to selling dialysis products, Fresenius Medical Care also offers dialysis treatment and associated laboratory services to patients through its network of 3,690 clinics.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    EMEA and APAC: Fresenius Medical Care’s Dialysis Products Business

    In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    North America: Fresenius Medical Care’s Major Target Market in 2017

    In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fresenius Medical Care’s Net Profit Margins Could Fall Slightly

    For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s net profit margins to be close to 6.2%, which is a YoY decline of ~70 basis points.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fresenius Medical Care Could Report Modest Revenue Growth for 2017

    For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s revenues to be close to $20.8 billion, which equals YoY growth of ~16.0%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Analysts View Fresenius Medical Care and Its Peers in August 2017

    In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Baxter’s Renal Business Continues to Be Key Growth Driver

    In 1Q17, Baxter’s (BAX) renal segment reported revenues close to $896.0 million, which is an operational growth of around 2.0% YoY.

    By Margaret Patrick
  • uploads///Portfolio Breakdown of the HLMNX
    Fund Managers

    What’s the Sector Composition of HLMNX?

    The Harding Loevner International Equity Portfolio invests in developed markets except the US and in established companies from emerging and frontier markets.

    By David Ashworth
  • uploads///Portfolio Breakdown of the VGEAX
    Consumer

    What Makes the Virtus Greater European Opportunities Fund Unique?

    The Virtus Greater European Opportunities Fund’s assets were spread across 42 holdings as of June 2016, and it was managing assets worth $29 million.

    By David Ashworth
  • uploads///Portfolio Breakdown of the HLMNX
    Fund Managers

    The Harding Loevner International Equity Portfolio’s Moves in YTD 2016

    The Harding Loevner International Equity Portfolio (HLMNX) invests in developed markets except the US, as well as in established companies from emerging and frontier markets.

    By David Ashworth
  • Company & Industry Overviews

    Consumer Staples Delivered Top-Notch Performance for VGEAX

    The Virtus Greater European Opportunities Fund – Class A (VGEAX) rose 1.3% in 1Q16. It was the only fund to post gains for the period, making it the best of the 12 funds in this review.

    By David Ashworth
  • uploads///HLMNXs Top Invested Geographies
    Fund Managers

    What’s the Harding Loevner International Equity Portfolio’s Strategy?

    The Harding Loevner International Equity Portfolio invests in developed markets except the US and in established companies from emerging and frontier markets.

    By David Ashworth
  • uploads///Generic Pharma Sales
    Macroeconomic Analysis

    Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 1)

    Market Realist analysts recently conducted a Q&A with experts from VanEck on the generic pharmaceutical industry, a space that has attracted investor interest due to upside potential from brand name drugs coming off patent, cost saving pressure in the healthcare industry, and increased worldwide demand for prescription drugs (for more on these topics, please see […]

    By VanEck
  • Macroeconomic Analysis

    Industrials Dragged on FHJUX in Year-to-Date November 2015

    FHJUX was down 0.7% in November from one month ago. In the three- and six-month periods ended November 30, the fund rose 0.7% and fell 6.7%, respectively.

    By David Ashworth
  • uploads///Stimulus
    Macroeconomic Analysis

    European Central Bank’s Monetary Policy: Why the Disappointment?

    When monetary policy is eased, domestic currency can be expected to weaken.

    By David Ashworth
  • Macroeconomic Analysis

    Why Was the Columbia European Equity Fund Below Average?

    The Columbia European Equity Fund – Class A rose 5.1% in October 2015 from a month ago. It fell 3.7% in the six-month period ended October 30, 2015.

    By David Ashworth
  • uploads///cmn npm
    Earnings Report

    How Does Cantel Medical Compare to Its Peers?

    Cantel Medical outperformed its peers based on the net profit margin, current ratio, PE ratio, and PBV ratio. It outperformed its ETFs based on the PBV ratio.

    By Gabriel Kane
  • uploads///cmn pm
    Earnings Report

    Cantel Medical’s Revenue and Income Rose in 4Q15

    Cantel Medical reported net revenue of $151.255 million in 4Q15—a rise of 6.88% compared to the net revenue of $141.508 million in 3Q15.

    By Gabriel Kane
  • uploads///France
    Macroeconomic Analysis

    Service Sector Provides Optimism toward Growth in Germany

    Germany’s composite output index declined to 54.3 in September compared to 55.0 in August 2015.

    By Lara Sheldon
  • uploads///pricing e
    Healthcare

    Medtronic purchases Cardiocom: Bad for medical device industry?

    Medtronic has always been considered a bellwether for the medical device industry because of its pure focus on the device market. Yet that changed in mid-August, as Medtronic announced its acquisition of Cardiocom.

    By Amritpal Khalsa
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.